Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meropenem plasma and bone pharmacokinetics in foreign-body bone and joint infections: continuous versus intermittent infusion
2026-527210-22-00Phase 4Authorised
- Sponsor
- Parc de Salut Mar
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of meropenem in Bone and osteoarticular infections (BJI) (2 arms), sponsored by Parc de Salut Mar. Primary endpoints: Meropenem concentrations over time in plasma and bone tissue and Percentage of time free drug concentration exceeds minimum inhibitory concentration in plasma and bone tissue. Planned start Oct 2026; status: authorised.
02
Drugs
meropenem
03
Conditions
Bone and osteoarticular infections (BJI)
Beyond the preview
Go deeper on 2026-527210-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527210-22-00.